Mark Jones, MD
Interventional Pain Medicine · Boston, MANPI 1922452945
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Nevro Corp. at 41.0% of the total. 2025 is the largest year on record at $13,807, 7.0 times the $1,970 reported in 2020. Among interventional pain medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $164.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$20K
- Spinefrontier, Inc.$13K
- Medtronic$8K
- MML US, Inc.$2K
- Stratus Medical, LLC$2K
- Boston Scientific$976
- plus $3K from 23 others
Across 38 payments — averaging $3437.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$128K
- Globus Medical$3K
What the payments were for
- Consulting fees$6,04313%
- Speaking & faculty fees$17,90537%
- Grants$4,79210%
- Travel & lodging$7,01315%
- Food & beverage$12,23625%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 108 | $19,695 |
| Spinefrontier, Inc. | 20 | $12,971 |
| Medtronic(2 entities) | 27 | $7,988 |
| MML US, Inc. | 16 | $2,211 |
| Stratus Medical, LLC | 5 | $1,501 |
| Boston Scientific | 22 | $976 |
| SPR Therapeutics, Inc | 9 | $601 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $266 |
| Collegium Pharmaceutical, Inc. | 21 | $260 |
| Globus Medical | 4 | $243 |
| Vertos Medical, Inc. | 4 | $173 |
| Tersera Therapeutics LLC | 9 | $166 |
| Lilly USA, LLC | 9 | $142 |
| Abbott | 6 | $104 |
| Nalu Medical, Inc. | 3 | $82 |
| Hikma Pharmaceuticals USA | 4 | $76 |
| AbbVie | 4 | $72 |
| Spinal Simplicity, LLC | 2 | $72 |
| Painteq LLC | 3 | $56 |
| Amgen(2 entities) | 3 | $51 |
| Relievant Medsystems, Inc. | 2 | $51 |
| Bsn Medical Inc | 1 | $48 |
| Curonix LLC | 2 | $45 |
| Scilex Pharmaceuticals Inc. | 2 | $31 |
| Biotronik NRO, Inc. | 1 | $26 |
| Saluda Medical Americas, Inc. | 1 | $25 |
| Avanos Medical | 1 | $22 |
| Si-bone, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$15,147
- InSpan$12,574
- SIJFuse$12,574
- NanoFuse$12,574
- FacetFuse$11,742
- SYNCHROMED$4,375
- SYNCHROMEDII$2,917
- Omnia$1,894
- ReActiv8$1,858
- Nimbus$1,479
- Vyrsa V1$500
- WaveWriter Alpha Prime 16$392
- INTELLIS ADAPTIVESTIM$322
- RELISTOR$266
- mild Device Kit$117
- SPRINT PNS System$109
How this compares
$47,989 in reported general payments places this provider in the 95th percentile of 22 interventional pain medicine providers in Massachusetts.
See all interventional pain medicine providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 16 | $22,616 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 488 | $20,007 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $18,847 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 327 | $15,529 |
| BelbucaBuprenorphine Hcl | 26 | $14,637 |
| Buprenorphine | 51 | $8,777 |
| MovantikNaloxegol Oxalate | 20 | $7,894 |
| Gabapentin | 413 | $6,342 |
| LinzessLinaclotide | 12 | $6,072 |
| Pregabalin | 207 | $3,740 |
| Naloxone Hcl | 62 | $3,649 |
| Tizanidine Hcl | 170 | $2,872 |
| Oxycodone Hcl | 177 | $2,646 |
| Methocarbamol | 81 | $1,934 |
| Cyclobenzaprine Hcl | 143 | $1,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $260 | $14,63726 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $76 | $9,74078 claims |
| AbbVieLinzess | $72 | $6,07212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 interventional pain medicine providers in Massachusetts.
Other interventional pain medicine in Boston
- Warren Mackie-JenkinsBoston$65K
- Frederic GergesBoston$21K
- Elvis GuzmanBoston$4K
- David DibenedettoWaltham$17K
- Anil KumarStoneham$8K
- Omar QureshiFitchburg$7K
- Rami RustumMethuen$6K
- Janet PearlFramingham$5K
- Yuri KhibkinHolyoke$5K
- Erica BialBurlington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.